ted
ross
phd
overview
dengu
fever
df
preval
arthropodborn
viral
ill
human
caus
dengu
viru
denv
serotyp
denv
denv
transmit
human
primarili
aed
aegypti
mosquito
fig
denv
member
flavivirida
famili
relat
virus
caus
yellow
fever
japanes
st
loui
west
nile
encephalitid
infect
denv
caus
spectrum
clinic
diseas
rang
acut
debilit
selflimit
febril
ill
df
lifethreaten
hemorrhag
capillari
leak
syndrom
dengu
hemorrhag
feverdengu
shock
syndrom
dhfdss
denv
caus
estim
million
case
df
case
dhf
per
year
worldwid
billion
peopl
risk
infect
present
approv
antivir
treatment
vaccin
use
therapi
support
natur
fig
epidem
dhf
first
recogn
southeast
asia
becom
lead
caus
hospit
death
among
children
mani
countri
region
dhf
began
second
expans
asia
countri
dhf
endem
epidem
becom
progress
larger
last
year
box
first
indigen
transmiss
dengu
unit
state
year
occur
later
infect
also
occur
texa
dengu
outbreak
occur
hawaii
spread
aed
albopictu
mosquito
america
seen
dramat
rise
emerg
dengu
case
fig
mosquito
vector
dengu
erad
region
part
pan
american
health
organ
yellow
fever
erad
campaign
aegypti
erad
program
offici
discontinu
unit
state
western
hemispher
region
lead
reinfest
mosquito
vector
countri
geograph
distribut
aegypti
wider
distribut
erad
program
dengu
endem
much
western
hemispher
hyperendem
presenc
multipl
circul
serotyp
widespread
countri
epidem
caus
multipl
serotyp
frequent
denv
envelop
viru
singlestrand
positivesens
kilobas
rna
genom
translat
singl
polyprotein
cleav
structur
protein
capsid
c
premembranemembran
prmm
envelop
e
nonstructur
ns
protein
virusand
hostencod
proteas
structur
compon
requir
capsid
format
c
assembl
viral
particl
prm
e
ns
protein
contain
serin
proteas
atpdepend
helicas
requir
viru
polyprotein
process
methyltransferas
rnadepend
rna
polymeras
cofactor
proteas
implic
block
interferon
ifn
respons
either
unknown
incomplet
understood
function
ns
protein
appear
necessari
effici
replic
primari
denv
infect
viru
enter
target
cell
e
protein
adher
cell
surfac
receptor
dendrit
cellspecif
intercellular
adhes
nonintegrin
dcsign
dendrit
cell
viral
uptak
occur
receptormedi
endocytosi
endosom
acidif
induc
conform
chang
e
protein
result
fusion
viral
endosom
membran
nucleocapsid
releas
cytoplasm
viru
genom
replic
occur
discret
domain
within
endoplasm
reticulum
er
viru
assembl
occur
er
virion
exocytos
via
golgideriv
secretori
vesicl
follow
bite
mosquito
usual
aegypti
albopictu
denv
caus
rang
mildtosever
ill
mosquito
erad
program
offici
discontinu
unit
state
gradual
weaken
elsewher
mosquito
began
reinfest
countri
erad
consequ
geograph
distribut
aegypti
much
wider
erad
program
correspond
increas
dengu
infect
distinct
serotyp
denv
primari
infect
one
denv
serotyp
provid
lifelong
immun
specif
serotyp
howev
individu
infect
differ
serotyp
denv
increas
dengu
viru
risk
sever
dengu
diseas
occur
serotyp
therefor
region
multipl
endem
serotyp
risk
sever
diseas
higher
pathogenesi
dhfdss
sever
form
denv
infect
reflect
complex
interplay
host
immun
respons
viral
determin
virul
epidemiolog
studi
suggest
immun
system
linkag
increas
risk
dhf
secondari
denv
infect
fig
reinfest
aegypti
america
unfortun
success
erad
campaign
sustain
begin
earli
began
disband
mani
countri
channel
limit
resourc
area
consequ
aegypti
began
reinfest
countri
erad
compar
map
mosquito
seen
reestablish
throughout
central
america
south
america
mosquito
spread
number
frequenc
dengu
epidem
increas
dengu
hemorrhag
fever
activ
america
courtesi
cdc
avail
http
wwwcdcgovncidoddvbiddengu
children
within
first
year
life
born
denvimmun
mother
observ
hypothesi
antibodydepend
immun
enhanc
ade
infect
emerg
support
ade
pathogenesi
concept
antibodi
enhanc
denv
infect
monocyt
vitro
correl
increas
risk
dhf
peak
viremia
increas
patient
sever
secondari
denv
infect
differ
specif
genet
determin
among
viral
isol
may
also
affect
virul
denv
strain
fail
caus
sever
diseas
final
patholog
cytokin
respons
occur
extens
tcell
activ
may
contribut
capillari
leak
syndrom
associ
dhf
elev
level
cytokin
includ
ifng
tumor
necrosi
factor
tnf
g
interleukin
il
extent
correl
sever
diseas
diseas
sever
associ
activ
cell
expans
serotypereact
lowaffin
denvspecif
cell
produc
high
level
vasoact
cytokin
dengu
fever
may
present
mani
form
undifferenti
febril
ill
maculopapular
rash
particularli
children
flulik
symptom
classic
dengu
symptom
fever
headach
bone
joint
pain
muscular
pain
rash
pain
behind
eye
petechi
hemorrhag
often
prolong
fatigu
depress
dengu
epidem
hemorrhag
complic
may
also
appear
bleed
gum
noseble
bruis
case
fatal
due
df
low
wherea
dhf
mortal
fairli
high
specif
treatment
dengu
fever
except
symptomat
treatment
rest
rehydr
recogn
warn
sign
symptom
dengu
infect
critic
appropri
diagnosi
treatment
fig
dhf
character
spontan
bleed
plasma
leakag
fever
thrombocytopenia
four
clinic
manifest
need
observ
classifi
dhf
includ
fever
hemorrhag
episod
presenc
least
one
follow
posit
tourniquet
test
result
also
call
capillari
fragil
test
clinic
diagnost
method
determin
patient
hemorrhag
tendenc
assess
fragil
capillari
wall
petechia
ecchymos
purpura
bleed
mucosa
gastrointestin
tract
inject
site
other
plasma
leakag
due
increas
capillari
permeabl
thrombocytopenia
less
moderatetomark
thrombocytopenia
concurr
hemoconcentr
distinct
clinic
laboratori
find
dhf
howev
distinguish
dhf
df
observ
plasma
leakag
manifest
rise
hematocrit
valu
ie
hemoconcentr
must
observ
fig
normal
cours
dhf
last
day
appropri
intens
mainten
circul
fluid
volum
mortal
may
reduc
less
sever
df
dhf
case
hospit
serolog
test
necessari
confirm
case
dengu
howev
test
may
take
sever
day
develop
countri
may
resourc
perform
expens
confirmatori
assay
therefor
mani
suspect
case
dengu
fulli
diagnos
sever
case
dhf
patient
condit
may
suddenli
deterior
day
fever
temperatur
drop
follow
sign
circulatori
failur
patient
may
rapidli
go
critic
state
shock
dengu
shock
syndrom
die
within
hour
quickli
recov
follow
appropri
volum
replac
therapi
box
dss
sever
form
dhf
character
presenc
dhf
clinic
manifest
circulatori
failur
manifest
circulatori
failur
must
present
rapid
weak
puls
narrow
puls
pressur
hypotens
patient
age
cold
clammi
skin
alter
mental
state
establish
laboratori
diagnosi
dengu
infect
critic
diagnosi
dengu
major
challeng
diseas
surveil
case
diagnosi
dengu
virus
produc
asymptomat
infect
spectrum
clinic
ill
rang
mild
nonspecif
febril
ill
fatal
hemorrhag
diseas
import
risk
factor
dhf
includ
strain
serotyp
infect
viru
age
immun
statu
genet
predisposit
patient
common
method
detect
viru
propag
viru
serum
cell
cultur
detect
antidengu
antibodi
serolog
viru
cultur
vitro
detect
viral
rna
specif
dengu
viru
antigen
countri
access
sophist
laboratori
test
reli
identif
earli
clinic
simpl
laboratori
indic
provid
reliabl
diagnosi
dengu
hospit
earli
distinct
dengu
febril
ill
could
help
identifi
patient
monitor
sign
dhf
febril
ill
measl
typhoid
fever
leptospirosi
sever
acut
respiratori
syndrom
sar
produc
symptom
similar
df
present
ill
may
share
similar
clinic
featur
includ
headach
myalgia
rash
box
specif
antivir
elimin
viru
infect
individu
howev
support
care
treatment
effect
treat
df
paracetamol
antipyret
use
treat
fever
bone
pain
treat
analges
painkil
tablet
episod
dhfdss
mortal
rate
absenc
hospit
high
proper
treatment
intraven
fluid
replac
mortal
rate
greatli
reduc
multipl
correl
protect
describ
dengu
howev
primari
correl
seem
longterm
homotyp
protect
protect
antibodi
direct
surfac
e
glycoprotein
howev
antibodi
protein
show
protect
efficaci
passiv
transfer
antibodi
seroconvert
anim
result
decreas
infect
diseas
follow
challeng
addit
matern
antibodi
decreas
diseas
infant
use
vitro
neutral
assay
antibodi
direct
e
protein
prevent
viru
infect
antibodi
block
viral
attach
prevent
fusion
target
cell
neutral
viru
infect
addit
neutral
antibodi
mediat
cellmedi
cytotox
reduc
viru
infect
complementindepend
complementdepend
mechan
cellular
immun
respons
gener
weakli
protect
howev
respons
critic
viral
clearanc
innat
immun
respons
direct
ns
protein
put
ifn
antagonist
seem
mediat
viral
escap
current
denv
vaccin
approv
us
food
drug
administr
fda
four
relat
serolog
distinct
denv
caus
diseas
nonneutr
crossreact
antibodi
may
contribut
dhf
pathogenesi
via
antibodydepend
enhanc
therefor
effect
vaccin
must
induc
hightit
neutral
antibodi
strain
failur
could
increas
risk
sever
diseas
natur
challeng
circumv
problem
tetraval
liveattenu
candid
vaccin
vari
stage
develop
clinic
trial
tetraval
serolog
respons
observ
individu
mani
develop
high
titer
neutral
antibodi
despit
multipl
immun
addit
part
tetraval
vaccin
elicit
high
titer
immun
respons
lead
immunodomin
subunitbas
vaccin
purifi
protein
dna
plasmid
altern
vaccin
strategi
repeat
immun
purifi
recombin
denv
domain
iii
e
protein
diii
diiiencod
plasmid
induc
protect
antibodi
mice
albeit
fairli
low
neutral
titer
live
attenu
vaccin
nonrepl
vaccin
inactiv
viru
vaccin
viruslik
particl
dna
vaccin
develop
dengu
tabl
vaccin
elicit
protect
neutral
antibodi
vaccin
elicit
longlast
immun
specif
serotyp
denv
howev
poorli
crossreact
infect
anoth
subtyp
denv
